Littlejohns Peter, Barnett David, Longson Carole
National Institute of Clinical Excellence, London, UK.
Lancet Oncol. 2003 Apr;4(4):242-50. doi: 10.1016/s1470-2045(03)01036-2.
The National Institute for Clinical Excellence (NICE) was established to ensure faster and more equitable uptake of new technologies by the NHS, through the provision of guidance on clinical and cost-effectiveness. The treatment of cancer is one of the UK government's priority areas and a range of guidance products have been developed by NICE to support implementation of national plans for managing patients with cancer in England and Wales. In its first 3 years, NICE's main activity was the "Technology Appraisals Programme" and it has created considerable interest and some controversy. 15 (out of a total of 56) technology appraisals related to oncology have been completed and another four are in preparation. The open, transparent, and inclusive approach NICE has adopted in reaching its decisions highlights the difficult ethical issues that need to be addressed in seeking to balance individual desires with public-health requirements. In this review we describe the process of appraising technologies, and address the recent criticism of the appraisal programme with regard to treatment of patients with cancer.
英国国家卫生与临床优化研究所(NICE)的设立目的是,通过提供临床和成本效益方面的指导意见,确保国民医疗服务体系(NHS)更快、更公平地采用新技术。癌症治疗是英国政府的重点领域之一,NICE已制定了一系列指导产品,以支持在英格兰和威尔士实施国家癌症患者管理计划。在最初的3年里,NICE的主要活动是“技术评估计划”,该计划引起了广泛关注并引发了一些争议。(总共56项中)已完成了15项与肿瘤学相关的技术评估,另有4项正在筹备中。NICE在做出决策时所采用的开放、透明和包容的方法,凸显了在寻求平衡个人愿望与公共卫生需求时需要解决的棘手伦理问题。在本综述中,我们描述了技术评估过程,并回应了近期对该评估计划在癌症患者治疗方面的批评。